NCT06548958View on ClinicalTrials.gov

A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

March 30, 2027

Study Completion Date

June 30, 2027

Conditions
Malignant Hematological Diseases
Interventions
PROCEDURE

Second Stem Cell Transplantation (SCT2)

"1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion;~2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."

Trial Locations (1)

215006

RECRUITING

Hematology Department, The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER